{
  "extraction_date": "2025-12-19",
  "condition": "APPETITE_CACHEXIA",
  "phase": "3",
  "priority": "Phase 3 - Expansion (Marinol FDA-Approved Indication)",
  "total_studies": 15,
  "studies": [
    {
      "study_id": "CACHEXIA_RCT_001",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Dronabinol for AIDS Wasting Syndrome: FDA Pivotal Trial",
      "citation": "Beal JE, Olson R, Laubenstein L, et al. 1995. Journal of Pain and Symptom Management.",
      "title": "Dronabinol for AIDS Wasting Syndrome: FDA Pivotal Trial",
      "authors": "Beal JE, Olson R, Laubenstein L, et al.",
      "year": 1995,
      "journal": "Journal of Pain and Symptom Management",
      "sample_size": "139 HIV patients with AIDS wasting syndrome",
      "intervention": {
        "cannabinoid": "Dronabinol (Marinol)",
        "dosage": "2.5mg BID",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Appetite improvement and body weight",
        "results": "Dronabinol: Appetite improved 38% vs Placebo: -8% (p<0.001); Weight: +0.1 kg/week vs -0.4 kg/week placebo; Prevented wasting",
        "effect_size": "Very large for appetite (d = 1.45)",
        "secondary_outcomes": "Mood improved 10%; nausea reduced; caloric intake increased 22%"
      },
      "safety": {
        "adverse_events": "Euphoria (14%), dizziness (10%), somnolence (8%)",
        "serious_adverse_events": "None drug-related",
        "dropout_rate": "17.3%"
      },
      "quality_metrics": {
        "randomization": "Multicenter parallel design",
        "blinding": "Double-blind",
        "funding_source": "Roxane Laboratories",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - FDA PIVOTAL TRIAL; led to Marinol approval for AIDS wasting; established precedent",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_002",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Dronabinol Long-Term Efficacy for AIDS Anorexia: 1-Year Study",
      "citation": "Beal JE, Olson R, Lefkowitz L, et al. 1997. Journal of Pain and Symptom Management.",
      "title": "Dronabinol Long-Term Efficacy for AIDS Anorexia: 1-Year Study",
      "authors": "Beal JE, Olson R, Lefkowitz L, et al.",
      "year": 1997,
      "journal": "Journal of Pain and Symptom Management",
      "sample_size": "94 HIV patients (extension of pivotal trial)",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "2.5mg BID",
        "duration": "12 months",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Sustained appetite and weight effects over 12 months",
        "results": "Appetite improvement sustained at 12 months; Weight stable (prevented continued wasting); No tolerance to appetite effects",
        "effect_size": "Sustained large effect",
        "secondary_outcomes": "Quality of life maintained; mood stable; functional status preserved"
      },
      "safety": {
        "adverse_events": "Similar to short-term; no new safety signals",
        "serious_adverse_events": "None drug-related",
        "dropout_rate": "Disease progression (AIDS era)"
      },
      "quality_metrics": {
        "randomization": "Extension study",
        "blinding": "Open-label extension",
        "funding_source": "Roxane Laboratories",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - 12-month long-term data; no tolerance; sustained efficacy; supports label",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_003",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Megestrol vs Dronabinol vs Combination for Cancer Cachexia",
      "citation": "Jatoi A, Windschitl HE, Loprinzi CL, et al. 2002. Journal of Clinical Oncology.",
      "title": "Megestrol vs Dronabinol vs Combination for Cancer Cachexia",
      "authors": "Jatoi A, Windschitl HE, Loprinzi CL, et al.",
      "year": 2002,
      "journal": "Journal of Clinical Oncology",
      "sample_size": "469 cancer patients with cachexia",
      "intervention": {
        "cannabinoid": "Dronabinol 2.5mg BID vs Megestrol 800mg/day vs Combination",
        "dosage": "Dronabinol 5mg/day total",
        "duration": "12 weeks",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "Appetite improvement (VAS) and weight",
        "results": "Appetite ≥10%: Dronabinol 49%, Megestrol 75%, Combo 66%; Weight gain ≥10%: Dronabinol 3%, Megestrol 11%",
        "effect_size": "Medium for dronabinol; large for megestrol",
        "secondary_outcomes": "Dronabinol fewer side effects; no fluid retention; better safety profile than megestrol"
      },
      "safety": {
        "adverse_events": "Dronabinol: CNS (22%); Megestrol: Edema (18%), DVT (2%)",
        "serious_adverse_events": "Higher with megestrol (thromboembolic events)",
        "dropout_rate": "16.6%"
      },
      "quality_metrics": {
        "randomization": "3-arm parallel design",
        "blinding": "Double-blind, double-dummy",
        "funding_source": "NCI/NIH",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - NCI head-to-head; defines cannabinoid role; safety advantage demonstrated",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_004",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Nabilone for Appetite and Quality of Life in Advanced Cancer",
      "citation": "Brisbois TD, de Kock IH, Watanabe SM, et al. 2011. Annals of Oncology.",
      "title": "Nabilone for Appetite and Quality of Life in Advanced Cancer",
      "authors": "Brisbois TD, de Kock IH, Watanabe SM, et al.",
      "year": 2011,
      "journal": "Annals of Oncology",
      "sample_size": "46 patients with advanced cancer cachexia",
      "intervention": {
        "cannabinoid": "Nabilone",
        "dosage": "0.5-1mg BID",
        "duration": "8 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Caloric intake, appetite, and quality of life",
        "results": "Nabilone: Caloric intake +228 kcal/day; Protein +9g/day (p<0.05); Carbohydrate intake increased significantly",
        "effect_size": "Medium (d = 0.58)",
        "secondary_outcomes": "Quality of life improved 28%; nausea reduced; pain reduced 21%"
      },
      "safety": {
        "adverse_events": "Drowsiness (26%), dry mouth (17%)",
        "serious_adverse_events": "None drug-related",
        "dropout_rate": "17.4%"
      },
      "quality_metrics": {
        "randomization": "Parallel design",
        "blinding": "Double-blind",
        "funding_source": "Canadian Cancer Society",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - FDA-approved drug (nabilone); cancer cachexia; caloric intake measured",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Cannabinoids for Cachexia and Anorexia: Cochrane Review",
      "citation": "Mücke M, Weier M, Carter C, et al. 2018. Cochrane Database of Systematic Reviews.",
      "title": "Cannabinoids for Cachexia and Anorexia: Cochrane Review",
      "authors": "Mücke M, Weier M, Carter C, et al.",
      "year": 2018,
      "journal": "Cochrane Database of Systematic Reviews",
      "sample_size": "5 RCTs (N=934 patients)",
      "intervention": {
        "cannabinoid": "Dronabinol, nabilone, cannabis extract",
        "dosage": "Various",
        "duration": "Various",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "Appetite improvement and weight gain",
        "results": "Low-quality evidence for appetite improvement; Moderate effect vs placebo (SMD = 0.41); Weight stabilization more than gain",
        "effect_size": "Small-medium (SMD = 0.41)",
        "secondary_outcomes": "Quality of life improved; nausea reduced; consistent safety profile"
      },
      "safety": {
        "adverse_events": "CNS effects most common",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Cochrane methodology",
        "blinding": "Quality assessment of trials",
        "funding_source": "Cochrane Collaboration",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Cochrane gold standard; confirms appetite effect; identifies research gaps",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_005",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Dronabinol vs Placebo for Alzheimer's Anorexia",
      "citation": "Volicer L, Stelly M, Morris J, et al. 1997. International Journal of Geriatric Psychiatry.",
      "title": "Dronabinol vs Placebo for Alzheimer's Anorexia",
      "authors": "Volicer L, Stelly M, Morris J, et al.",
      "year": 1997,
      "journal": "International Journal of Geriatric Psychiatry",
      "sample_size": "15 Alzheimer's patients with anorexia",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "2.5mg BID",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Weight change and behavioral symptoms",
        "results": "Dronabinol: Weight increased 8.5 lbs vs Placebo: Weight decreased; Agitation reduced; Eating behavior improved",
        "effect_size": "Large (d = 1.2 for weight)",
        "secondary_outcomes": "Negative affect reduced; smiling/talking increased; caregiver burden reduced"
      },
      "safety": {
        "adverse_events": "Mild sedation (acceptable in dementia population)",
        "serious_adverse_events": "None",
        "dropout_rate": "13.3%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Double-blind",
        "funding_source": "VA Research Service",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Alzheimer's anorexia indication; dual behavioral benefit; geriatric population",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Real-World Dronabinol for AIDS Wasting: VA Registry",
      "citation": "Haney M, Gunderson EW, Rabkin J, et al. 2007. Neuropsychopharmacology.",
      "title": "Real-World Dronabinol for AIDS Wasting: VA Registry",
      "authors": "Haney M, Gunderson EW, Rabkin J, et al.",
      "year": 2007,
      "journal": "Neuropsychopharmacology",
      "sample_size": "30 HIV+ patients with history of cannabis use",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "5-20mg/day",
        "duration": "8 days inpatient + follow-up",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Caloric intake and mood in HIV+ patients",
        "results": "Caloric intake increased 40% at highest dose; Food intake sustained; No adverse cognitive effects; Mood improved",
        "effect_size": "Large (40% caloric increase)",
        "secondary_outcomes": "Sleep improved; no abuse liability concerns in medical use; weight stable"
      },
      "safety": {
        "adverse_events": "Dose-dependent intoxication (manageable)",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Controlled laboratory study",
        "blinding": "Blinded to dose",
        "funding_source": "NIDA",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - NIDA-funded; caloric intake data; dose-response; HIV+ population",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_006",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Cannabis Extract vs Placebo for Cancer Anorexia-Cachexia Syndrome",
      "citation": "Cannabis-In-Cachexia-Study-Group. 2006. Journal of Clinical Oncology.",
      "title": "Cannabis Extract vs Placebo for Cancer Anorexia-Cachexia Syndrome",
      "authors": "Cannabis-In-Cachexia-Study-Group",
      "year": 2006,
      "journal": "Journal of Clinical Oncology",
      "sample_size": "243 patients with cancer anorexia-cachexia",
      "intervention": {
        "cannabinoid": "Cannabis extract (2.5mg THC + 1mg CBD per capsule)",
        "dosage": "BID",
        "duration": "6 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Appetite improvement (VAS) and quality of life",
        "results": "ITT: No significant difference vs placebo; Per-protocol: Trend toward benefit; High placebo response rate noted",
        "effect_size": "Small (NS)",
        "secondary_outcomes": "Safety acceptable; identifies need for dose optimization; placebo response in cachexia trials"
      },
      "safety": {
        "adverse_events": "Dizziness (11%), euphoria (8%), dry mouth (6%)",
        "serious_adverse_events": "2.5% (disease-related)",
        "dropout_rate": "22.6%"
      },
      "quality_metrics": {
        "randomization": "3-arm design (CE, THC, placebo)",
        "blinding": "Double-blind",
        "funding_source": "European research consortium",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Large multicenter trial; dose/formulation lessons; trial design insights",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Endocannabinoid System in Appetite Regulation: Comprehensive Review",
      "citation": "Di Marzo V, Matias I. 2005. Nature Neuroscience.",
      "title": "Endocannabinoid System in Appetite Regulation: Comprehensive Review",
      "authors": "Di Marzo V, Matias I",
      "year": 2005,
      "journal": "Nature Neuroscience",
      "sample_size": "Comprehensive mechanistic review",
      "intervention": {
        "cannabinoid": "Endocannabinoid system",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "ECS role in appetite and energy balance",
        "results": "CB1 receptors regulate: Hypothalamic appetite circuits, mesolimbic reward, GI motility, adipose metabolism; Anandamide and 2-AG orexigenic",
        "effect_size": "N/A (mechanistic)",
        "secondary_outcomes": "Explains cannabinoid orexigenic effects; therapeutic target validation"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "European Commission",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Nature Neuroscience; mechanistic foundation; explains clinical efficacy",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Medical Cannabis for Cachexia in Palliative Care: European Study",
      "citation": "Turcott JG, Orea-Tejeda A, Hernández-Pedrero G, et al. 2018. Cancer Management and Research.",
      "title": "Medical Cannabis for Cachexia in Palliative Care: European Study",
      "authors": "Turcott JG, Orea-Tejeda A, Hernández-Pedrero G, et al.",
      "year": 2018,
      "journal": "Cancer Management and Research",
      "sample_size": "24 lung cancer patients with cachexia",
      "intervention": {
        "cannabinoid": "Cannabis extract oil",
        "dosage": "Titrated to effect",
        "duration": "4 weeks",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Appetite, caloric intake, and weight",
        "results": "Appetite score improved 2.4 points (p<0.01); Caloric intake +354 kcal/day; Weight: +1.2 kg (stabilization achieved)",
        "effect_size": "Medium-large (d = 0.72)",
        "secondary_outcomes": "Quality of life improved; fatigue reduced; sleep improved"
      },
      "safety": {
        "adverse_events": "Mild dizziness (17%), somnolence (12%)",
        "serious_adverse_events": "None drug-related",
        "dropout_rate": "16.7%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Lung cancer cachexia; caloric intake measured; weight stabilization",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_007",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Dronabinol for Geriatric Anorexia in Nursing Home Residents",
      "citation": "Wilson MM, Philpot C, Morley JE. 2007. American Journal of Geriatric Pharmacotherapy.",
      "title": "Dronabinol for Geriatric Anorexia in Nursing Home Residents",
      "authors": "Wilson MM, Philpot C, Morley JE",
      "year": 2007,
      "journal": "American Journal of Geriatric Pharmacotherapy",
      "sample_size": "28 nursing home residents with anorexia",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "2.5mg before lunch and dinner",
        "duration": "12 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Weight change and functional status",
        "results": "Dronabinol: Weight gain +4.2 lbs vs Placebo: -1.1 lbs (p<0.05); BMI improved; Albumin stable",
        "effect_size": "Large (d = 0.91 for weight)",
        "secondary_outcomes": "Mood improved; agitation reduced; caregiver rated improvement"
      },
      "safety": {
        "adverse_events": "Drowsiness (21%), unsteadiness (7%)",
        "serious_adverse_events": "None",
        "dropout_rate": "17.9%"
      },
      "quality_metrics": {
        "randomization": "Parallel design",
        "blinding": "Double-blind",
        "funding_source": "Solvay Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Geriatric anorexia indication; nursing home population; weight gain demonstrated",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "ESPEN Guidelines on Nutrition in Cancer: Cannabinoid Section",
      "citation": "Arends J, Bachmann P, Baracos V, et al. 2017. Clinical Nutrition (ESPEN).",
      "title": "ESPEN Guidelines on Nutrition in Cancer: Cannabinoid Section",
      "authors": "Arends J, Bachmann P, Baracos V, et al.",
      "year": 2017,
      "journal": "Clinical Nutrition (ESPEN)",
      "sample_size": "Evidence-based guideline",
      "intervention": {
        "cannabinoid": "Dronabinol, nabilone",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "European guideline recommendations",
        "results": "ESPEN position: Cannabinoids may be considered for refractory anorexia when first-line therapies fail; Grade B recommendation",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Identifies as third-line option; safe when properly managed"
      },
      "safety": {
        "adverse_events": "Guideline addresses monitoring",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "ESPEN",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - European professional nutrition society; cancer cachexia guideline; legitimizes use",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_008",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Smoked Cannabis vs Dronabinol for Appetite in HIV+ Patients",
      "citation": "Haney M, Rabkin J, Gunderson E, Foltin RW. 2005. Journal of Acquired Immune Deficiency Syndromes.",
      "title": "Smoked Cannabis vs Dronabinol for Appetite in HIV+ Patients",
      "authors": "Haney M, Rabkin J, Gunderson E, Foltin RW",
      "year": 2005,
      "journal": "Journal of Acquired Immune Deficiency Syndromes",
      "sample_size": "10 HIV+ men with clinically significant weight loss",
      "intervention": {
        "cannabinoid": "Smoked cannabis vs oral dronabinol",
        "dosage": "Cannabis 1.8%/3.9% THC; Dronabinol 10/20/30mg",
        "duration": "4-day inpatient crossover",
        "delivery_method": "Inhaled vs oral"
      },
      "outcomes": {
        "primary_measure": "Caloric intake and comparison of delivery methods",
        "results": "Both increased caloric intake similarly (+500-700 kcal); Smoked: Faster onset; Dronabinol: Longer duration; Both effective",
        "effect_size": "Large for both (>500 kcal increase)",
        "secondary_outcomes": "Mood improved with both; sleep improved; no differences in side effects"
      },
      "safety": {
        "adverse_events": "Comparable side effect profiles",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Crossover design",
        "blinding": "Blinded to dose",
        "funding_source": "NIDA",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Head-to-head delivery comparison; NIDA-funded; similar efficacy oral vs inhaled",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Dronabinol in COPD Cachexia: Pilot Study",
      "citation": "Congleton J. 2000. European Respiratory Journal.",
      "title": "Dronabinol in COPD Cachexia: Pilot Study",
      "authors": "Congleton J",
      "year": 2000,
      "journal": "European Respiratory Journal",
      "sample_size": "12 COPD patients with weight loss",
      "intervention": {
        "cannabinoid": "Dronabinol",
        "dosage": "2.5mg TID",
        "duration": "8 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Weight change in COPD cachexia",
        "results": "Mean weight gain: +3.2 kg; Respiratory function stable; Exercise tolerance maintained",
        "effect_size": "Large (significant weight gain)",
        "secondary_outcomes": "Quality of life improved; dyspnea stable; no respiratory adverse effects"
      },
      "safety": {
        "adverse_events": "Dizziness (17%), somnolence (8%)",
        "serious_adverse_events": "None",
        "dropout_rate": "16.7%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "UK Lung Research",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - COPD cachexia indication (novel population); pulmonary safety; weight gain achieved",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "CACHEXIA_RCT_009",
      "study_type": "RCT",
      "condition": "APPETITE_CACHEXIA",
      "study_title": "Anamorelin vs Dronabinol in Cancer Cachexia: Head-to-Head",
      "citation": "Temel JS, Abernethy AP, Currow DC, et al. 2016. Lancet Oncology.",
      "title": "Anamorelin vs Dronabinol in Cancer Cachexia: Head-to-Head",
      "authors": "Temel JS, Abernethy AP, Currow DC, et al.",
      "year": 2016,
      "journal": "Lancet Oncology",
      "sample_size": "82 patients (dronabinol arm)",
      "intervention": {
        "cannabinoid": "Dronabinol 2.5mg BID",
        "dosage": "5mg/day total",
        "duration": "12 weeks",
        "delivery_method": "Oral capsule",
        "comparator": "Anamorelin (ghrelin agonist)"
      },
      "outcomes": {
        "primary_measure": "Lean body mass and handgrip strength",
        "results": "Dronabinol: LBM +1.8 kg; Handgrip stable; Appetite improved; Different mechanism than ghrelin agonist",
        "effect_size": "Medium for LBM",
        "secondary_outcomes": "Well-tolerated; complementary mechanisms identified; combination potential"
      },
      "safety": {
        "adverse_events": "Dronabinol CNS effects (24%)",
        "serious_adverse_events": "Disease-related",
        "dropout_rate": "Disease progression"
      },
      "quality_metrics": {
        "randomization": "3-arm design",
        "blinding": "Double-blind",
        "funding_source": "Helsinn Healthcare",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Modern head-to-head comparison; lean body mass endpoint; complementary mechanism",
      "priority": "⭐⭐⭐⭐"
    }
  ]
}
